Participación española en el VII PM de Nanomedicina (R+D): Nanother, Óscar Salas (Gaiker) y

NANOTHER
Integration of novel NANOparticle based technology for
THERapeutics and diagnosis of different types of cancer
Información General
•
Fundación Privada (Sin ánimo de lucro)
• Año de creación: 1985
• Ubicación: Parque Tecnológico de Bizkaia
• Superficie Disponible: 8.490 m2
ƒ Personal Contratado
2007
2008
119
127
„
Estancias en Formación
22
20
„
Empresas Clientes
316
350
„
Ingresos Totales
10,19 M€
11,35 M€
La Misión
Nuestra Razón de Ser
GAIKER es un Centro Tecnológico cuya razón de ser es
la investigación y la prestación de soluciones
tecnológicas fiables e innovadoras que aporten valor a
la empresa, contribuyendo a su desarrollo tecnológico y
a su competitividad mediante la generación, captación,
adaptación y transferencia de tecnologías innovadoras
de forma sostenible. Además asume el desarrollo de
oportunidades en actividades económicas emergentes,
todo ello dentro de un marco de colaboración con otros
agentes.
Áreas de Conocimiento y Líneas Tecnológicas
„
PLÁSTICOS Y COMPOSITES
3Formulación y Transformación de
Polímeros (FORTRAP)
3 Nanomateriales y Materiales Inteligentes
(NANOMAT)
„
MEDIO AMBIENTE
3 Tecnologías Limpias (TECLIM)
3 Reciclado y Sostenibilidad (RESOST)
„
BIOTECNOLOGÍA
3 Biotecnología Funcional (BIOFUND)
3 Biotecnología Industrial (BIOIND)
NANOTHER
Integration of novel NANOparticle based technology for
THERapeutics and diagnosis of different types of cancer
NANOTHER
LIST OF BENEFICIARIES
11 538 574 €
8 408 843 €
NANOTHER
Strategic level
General Assembly
(Decide)
Chairman: GAIKER, all members: 1 representative/partner
„
Management level
„
Executive committee
(Monitor and decide)
Chairman: GAIKER, ALMA, SP learders,
Exploitation manager, Dissemination manager
 European Commission 
≥ 4 CONTACT PEOPLE PER GROUP
= ~72
CONTACTS
Project Management Team
(Day-to-day management)
~72 PERSONALITIES, OPINIONS,
IDEAS…
Chairman: GAIKER, ALMA, Exploitation Manager,
Manager
X 9 COUNTRIES+ 9 LANGUAGES XDissemination
9 CULTURES
Implementation level
„
Advisory board
SPL0
Alma
SPL1
LCPO
SPL2
JRC
SPL3
VC
SPL4
INSTM
SPL5
COLORITA
SPL6
Gaiker
WPLs
WPLs
WPLs
WPLs
WPLs
WPLs
WPLs
NANOTHER
FUNCTIONAL NANOCARRIER
- Activated system
- Target tumour cells
KEY :
Fluorescent molecule
Drug
Cyclodextrin
Antibody
THERANOSTICS
Studied of combined approach:
functionalities for diagnosis and
therapeutic action by magnetic
nanocarrier systems or maybe
drug delivery
Magnetic core
Polymer coating
THERAPY
-Delivery sRNA
- Release of drug compounds
-Hyperthermic activation
OBJETIVOS
Leads to destruction of tumor cells
DIAGNOSIS of tumour
cells by imaging of
activated fluorescent
nanocarrier system
Leads to destruction of tumor cells
n
n
n
Imaging
Tumour cells
n
NANOTHER
NANOPARTICLES
1) Hybrid
magnetic particles
2) Polymer NPs –
• Biodegradable
• Bioedible
• pH sensitive
• thermosensitive
systems
Drug compounds
Doxorubicin
Taxol
RNAi
Camptothecin ( and derivatives)
Marine compounds
Antibodies + ligands
• Colon cancer = CEA / EGFR
• Breast cancer = ERBB2
• Bone cancer = biphosphonate
Imaging
Therapy
Imaging
Diagnostics
NP Specifications &
functionalisation
NANOTHER Strategy
Theranostics
Imaging techniques
• MRI
• SPECT
• PET
Loading Mode =>
1)
Encapsulation
2)
Sorption
3)
Conjugation
Release Mode =>
1)
Biodegradable,
2)
Bioerodible,
3)
pH sensitive
4)
Thermosensitive systems
Toxicology
&
Biocompatibility
Efficiency
&
Biodistribution
In vitro & in vivo models
NANOTHER
NANOTHER R&D
Concept
Laboratory
(in vitro / in vivo )
Nanoparticles (polymer micelle & magnetic)
Targeting => Antibody & ligand (production & linkage)
Therapy => Drug compounds (loading mode, release mode …)
Theranostics => combined diagnostic & therapeutic approach
Testing of functionalised nanoparticles => breast, colon & bone cancer
(toxicology & biocompatibility, efficiency & biodistribution)
Nanoparticles
Antibody & ligand
linkage
Nano
materials
Drug compound
& fluorescent
molecule
attachm ent
Nano
intermediates
Diagnosis &
therapy in cancer
=> Toxicology &
biocompatibility,
efficiency &
biodistribution
Nano
Products
NANOTHER – R&D Value chain
Development
Scale-up
NANOTHER
Nano
system
Selection
Feedback
System
SP3
Targeting &
Diagnosis
SP4
Therapy
SP5
Theranostics
Nano
system
Selection
NANOTHER
Simplified Pert Diagram
SP6 Efficiency & biodistribution
SP0 Project Management & Dissemination
SP2 Toxicology & Biocompatibility
SP1
NP Functional
specifications
+ selection